| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 4, 2013 | $14M round for ‘cross-kingdom vaccine’ maker will fund trials in prevention of yeast infections | The vaccine contains a recombinant form of Als3, a protein found on the surface of Candida albicans which helps it bind to and invade human endothelial cells. The synthetic version of the protein used in the vaccine is produced by the ferme... |
| Sep 24, 2013 | Cancer patient’s compassionate use conundrum incites a social media ambush on BioMarin | Unable to operate on her anymore, Dr. Charles Levenback at the MD Anderson Cancer Center suggested she look for alternative options — namely, BioMarin’s drug. The problem is that BioMarin, at least for now, is conducting a Phase 3 trial of ... |
| Sep 9, 2013 | Investors pump $19.8M into a medical device that seals varicose veins with glue | Rather than using liquid chemicals to scar and close off twisted and inflamed veins, or treating them with laser or heat, Sapheon takes the approach of gluing the affected veins shut to re-route blood to other healthy veins in the leg. It’s... |
| Aug 22, 2013 | Navidea’s Alzheimer’s imaging agent moves into Phase 3 with Siemens deal, SBIR grant | The presence of amyloid plaques in the brain has been considered a hallmark of neurodegenerative disease for years now. So the thought is that being able to see that those plaques are building up would give clinicians a better way to diagno... |
| Aug 13, 2013 | From inhalable insulin to vaccines: 5 diabetes companies to watch | Then there’s Pepex Biomedical, which is developing a line of all-in-one blood glucose meters that use biosensors and eliminate the need for testing strips. It’s also working on turning the technology into a cartridge that attaches to a smar... |
| Jun 4, 2013 | Venture firms bet $41M more on P&G spinout developing oral anemia drug | “Besides driving the company toward Phase 3 readiness, this financing also gives the company an opportunity to validate the drug’s utility in a broader range of patients,” said Dr. Daniel Kosoy, a partner at Athenian Venture Partners.
Disea... |
| Mar 20, 2013 | Medical device maker raising $13M for minimally invasive treatment of A-fib | nContact’s system is being studied in an ongoing safety and efficacy trial in patients with long-standing persistent atrial fibrillation, according to ClinicalTrials.gov. The company’s media representative could not be reached for an update... |
| Feb 5, 2013 | $11M round will fund Novian’s trial of laser- based minimally invasive breast cancer device | Already approved by the U.S. Food and Drug Administration for use in treating benign tumors, Novian’s device is now being tried to evaluate the rate of complete tumor ablation of breast cancers smaller than 2 cm in size. The company says th... |
| Jan 24, 2013 | Biopharma testing celiac disease drug to break down gluten | Celiac disease is characterized by an immune response elicited by the ingestion of gluten, a storage protein found in wheat, rye and barley. That response affects the process of the small intestine and can inhibit the absorption of nutrient... |
| Jan 10, 2013 | Investors have put $15.5M behind cancer drug startup to revive shelved Hsp90 inhibitor | Here’s what we’ve learned about Esanex since May: It’s apparently a resurrection of Serenex, a North Carolina-based cancer drug company that was acquired by Pfizer in 2008 when it was in phase 1 development. Several former Serenex executive... |
| Jan 3, 2013 | Implantable device addresses the cause of severe GERD with electrical stimulation | While antacids, H2 blockers and proton pump inhibitors can be used to treat occasional heartburn, there is concern about side effects from long-term use of H2 blockers and PPIs, which suppress the production of stomach acid.
EndoStim’s devi... |
| Sep 13, 2012 | Hepatitis drug developer nears completion of $5 million round | Solution/product: Eiger develops treatments for hepatitis. According to its website, it has two hepatitis delta virus drug candidates (EBP921 and EBP994) in phase 2 development as well as a hepatitis C drug.
Infection with hepatitis D occur... |
| Sep 5, 2012 | Maker of stem cell modulators brings in $9.2 million for blood cancer trials | Location: San Diego, California.
Solution/product: Fate develops stem cell modulators. Its lead drug, ProHema, uses a small molecule (FT1050) to modulate hematopoietic stem cells (HSC), or blood-forming cells, that are transplanted to resto... |
| Aug 27, 2012 | Hoping to have first FDA-approved lactose intolerance treatment, phase 2 firm raises $5.8M | In controlled phase 2 study results released earlier this year, Ritter said that RP-G28 reduced digestive symptoms associated with lactose intolerance by 56 percent in patients (an original announcement about the study said the trial was ex... |
| Aug 22, 2012 | Ophthalmology incubator’s latest spinout — backed by big VC firms — raises $8 million | Location: Menlo Park, California.
Solution/product: This is the fifth and most recent spinout of ForSight Labs, an incubator formed by Morgenthaler Ventures, Split Rock Partners and Versant Ventures to launch startups focused on developing ... |
| Aug 21, 2012 | Relypsa snatches $80M for drug to treat high potassium in kidney disease, diabetes | City, State: Santa Clara, California
Solution/Product: Patiromer, or RLY5016, is a non-absorbed oral potassium binder being developed for the treatment of hyperkalemia in patients with chronic kidney disease, diabetes and heart failure. Hyp... |
| Aug 15, 2012 | Clinical stage Alzheimer’s drug hopeful locks up $2 million in most recent financing | Location: San Diego, California.
Solution/product: Sonexa develops drug treatments for Alzheimer’s disease and related disorders. Its lead compound, ST101, is an oral drug intended to address the underlying pathology of Alzheimer’s. The com... |
| Aug 14, 2012 | Orphan drug firm with potential first treatment for HIBM raises $15 million | Solution/product: Ultragenyx is developing a sialic acid replacement therapy for treatment of the rare, progressive neuromuscular disease hereditary inclusion body myopathy. The disease is caused by a deficiency in sialic acid that causes m... |
| Jul 12, 2012 | Head and neck cancer treatment combines enzyme, existing drugs to make tumors self-destruct | PNP’s first product uses fludarabine phosphate, a U.S. Food and Drug Administration-approved chemotherapeutic agent already in clinical use for lymphocytic leukemia. In preclinical tests, the therapy killed both dividing and nondividing cel... |
| Jul 12, 2012 | Rex Health Ventures’ inaugural investment goes to RTP firm developing narcolepsy drug | Aerial, founded in 2011, has an investigative treatment for narcolepsy in phase 2 clinical trials, and an early stage biologic to treat pain licensed from UNC Chapel Hill. In a statement, company officials said the finances would be used fo... |
| Jul 3, 2012 | Pharma reviving Boehringer’s female sexual dysfunction drug gets $17.6M | Sprout is working with flibanserin, a compound it acquired from Boehringer Ingelheim, which originally developed the drug to treat depression before discovering its potential to treat HSDD. Sprout snatched up the compound after an U.S. Food... |
| Jun 28, 2012 | Bloodless glucometer uses light to check blood sugar in 20 seconds or less | Grove is one of several companies working on a noninvasive diabetes test using spectroscopy including DIRAmed, C8 MediSensors and InLight Solutions. Challenges in developing devices using this technique have included water interference and ... |
| Jun 5, 2012 | Cancer immunotherapy firm raises $1.5M, eyes strategic partners | At least 40 additional unique cancer immunotherapies are currently being tested, according to a report from MD Becker Partners LLC, including ones developed by Bavarian Nordic, GlaxoSmithKline, Bristol-Myers Squibb, Oncothyreo/Merck and Tra... |
| May 22, 2012 | Celebrex creator Talley working on a new anti-inflammatory drug for cancer | The well-documented side effects and dangers associated with COX-2 inhibitors have led to the removal of Bextra, another of Talley’s creations, and Vioxx from the market and an U.S. Food and Drug Administration-mandated “black box warning” ... |
| Orphan drug firm with potential first treatment for HIBM raises $15 million | Company name: Ultragenyx Pharmaceutical Inc.
Industry: Pharmaceuticals.
Location: Novato, California.
Solution/product: Ultragenyx is developing a sialic acid replacement therapy for treatment of the rare, progressive neuromuscular disease ... |
| Cancer patient’s compassionate use conundrum incites a social media ambush on BioMarin | For the past seven years, Andrea Sloan has been battling ovarian cancer. Now, she’s waging a second battle – this one against BioMarin Pharmaceuticals (NASDAQ:BMRN) – after being denied access to an experimental drug she thinks is her last ... |
| Cancer immunotherapy firm raises $1.5M, eyes strategic partners | A company developing products to restore the immune system of cancer patients has raised $1.5 million and is now looking for strategic partners.
IRX Therapeutics’ lead product, IRX-2, aims to correct dendritic cell and T-cell defects in can... |
| $11M round will fund Novian’s trial of laser- based minimally invasive breast cancer device | To help fund clinical trials of a minimally invasive, laser-based breast cancer therapy, Novian Health Inc. has rounded up $11 million from investors.
The Series A, led by iNetworks LLC, will support multicenter clinical trials of Novian’s ... |
| $14M round for ‘cross-kingdom vaccine’ maker will fund trials in prevention of yeast infections | Whereas most vaccines under development are designed to protect against one kind of pathogen, NovaDigm Therapeutics thinks a vaccine it’s developing could protect against certain fungal and bacterial infections caused by several species of ... |
| Medical device maker raising $13M for minimally invasive treatment of A-fib | A catheter and surgical ablation device maker working toward enabling less-invasive treatment of atrial fibrillation is looking for a big round of fresh capital for its next move.
Morrisville, North Carolina, company nContact Inc. has alrea... |
| Biopharma testing celiac disease drug to break down gluten | A biopharmaceutical company that’s already raised at least $42 million for its celiac disease drug now has $6 million more as it works through a second phase 2 trial.
Alvine Pharmaceuticals’ lead candidate is a mix of two recombinant gluten... |
| Rare disease biotech picks up $8M, drug development partner for DNA-based therapies | Amid somewhat of a renaissance in drug development for orphan diseases, another gene therapy company announced funding today for a potential treatment for a rare neurodegenerative condition called Friedreich’s ataxia (FRDA).
Agilis Biothera... |
| Hoping to have first FDA-approved lactose intolerance treatment, phase 2 firm raises $5.8M | For the millions of Americans who have some level of dairy intolerance, passing on the ice cream and cheese, or carrying supplements to take at the time of consumption, are the only options for avoiding the wrath of an angry gut. But a phas... |
| Implantable device addresses the cause of severe GERD with electrical stimulation | Researchers and medical device companies are using electrical stimulation in new products to address pain, sleep apnea, paralysis and ALS. But a young St. Louis company is applying electrical stimulation to gastroesophageal reflux disease t... |
| Investors have put $15.5M behind cancer drug startup to revive shelved Hsp90 inhibitor | A cancer pharmaceutical startup called Esanex generated lots of reader interest back in May when it began raising a $15 million round.
The latest U.S. Security and Exchange Commission filing from Esanex (in December) shows that the round wa... |
| Maker of stem cell modulators brings in $9.2 million for blood cancer trials | Company name: Fate Therapeutics.
Industry: regenerative medicine.
Location: San Diego, California.
Solution/product: Fate develops stem cell modulators. Its lead drug, ProHema, uses a small molecule (FT1050) to modulate hematopoietic stem c... |
| Venture firms bet $41M more on P&G spinout developing oral anemia drug | Akebia Therapeutics might be a bit behind in the race to develop a safer, oral drug for anemia, but it’s just gotten a big vote of confidence from investors in the form of a $41 million Series C.
Novartis Venture Fund, Kearny Venture Partne... |
| Hepatitis drug developer nears completion of $5 million round | A clinical-stage biopharmaceutical company developing drug candidates for hepatitis D and hepatitis C has secured $4.6 million of its targeted $5 million funding round.
Company name: Eiger Biopharmaceuticals.
Industry: Pharmaceuticals.
Loca... |
| Bloodless glucometer uses light to check blood sugar in 20 seconds or less | When will diabetics in the U.S. get a bloodless glucometer that will allow them to check their blood sugar without a finger prick?
The short answer is, we don’t know for sure. But a company that’s wrapped up initial testing of its bloodless... |
| Pharma reviving Boehringer’s female sexual dysfunction drug gets $17.6M | Using a compound that Boehringer Ingelheim abandoned two years ago, Sprout Pharmaceuticals is taking a $20 million step toward developing a drug therapy specifically for hypoactive sexual desire disorder (HSDD) in women.
The Raleigh, North ... |
| From inhalable insulin to vaccines: 5 diabetes companies to watch | With an estimated 370 million people expected to have diabetes by 2030, the already $41 million market for diabetes management products is set to skyrocket over the next several years.
Fittingly, creating devices, drugs and services aimed a... |
| Head and neck cancer treatment combines enzyme, existing drugs to make tumors self-destruct | A clinical-stage biopharmaceutical company is testing a new targeted cancer treatment based on the notion that solid tumors can be compelled to develop their own chemotherapy and self-destruct.
In PNP Therapeutics Inc.’s platform technology... |
| Investors pump $19.8M into a medical device that seals varicose veins with glue | A new, minimally invasive treatment uses ultrasound and medical glue to seal up potentially problematic varicose veins in the leg.
Investors have just injected $19.8 million into Morrisville, North Carolina-based medical device company Saph... |
| Relypsa snatches $80M for drug to treat high potassium in kidney disease, diabetes | Name of Company: Relypsa Inc.
Industry: Biopharmaceuticals
City, State: Santa Clara, California
Solution/Product: Patiromer, or RLY5016, is a non-absorbed oral potassium binder being developed for the treatment of hyperkalemia in patients w... |
| Rex Health Ventures’ inaugural investment goes to RTP firm developing narcolepsy drug | A $10 million venture fund launched earlier this year by the private, nonprofit hospital Rex Healthcare has found its first portfolio company in Morrisville, North Carolina-based Aerial BioPharma, which develops biologics and small molecule... |
| Clinical stage Alzheimer’s drug hopeful locks up $2 million in most recent financing | Company name: Sonexa Therapeutics Inc.
Industry: Pharmaceuticals.
Location: San Diego, California.
Solution/product: Sonexa develops drug treatments for Alzheimer’s disease and related disorders. Its lead compound, ST101, is an oral drug in... |
| Ophthalmology incubator’s latest spinout — backed by big VC firms — raises $8 million | Company name: ForSight Vision 5.
Industry: Ophthalmology.
Location: Menlo Park, California.
Solution/product: This is the fifth and most recent spinout of ForSight Labs, an incubator formed by Morgenthaler Ventures, Split Rock Partners and ... |
| Celebrex creator Talley working on a new anti-inflammatory drug for cancer | In his latest project, Dr. John Talley, the lead scientist behind Pfizer’s Celebrex and seven other drugs that have been marketed in the U.S., is trying his hand at developing a cancer medication with improved efficacy and safety.
He’s the ... |
| Navidea’s Alzheimer’s imaging agent moves into Phase 3 with Siemens deal, SBIR grant | Navidea Biopharmaceuticals (NYSE:NAVB) is getting some financial support from the NIH for its Alzheimer’s diagnostic technology as it advances into Phase 3 development.
The National Institute of Aging awarded up to $1.8 million for a late-s... |